GlassScriptPhysician profile
John M Lawrence
NPI 1235401712
$6,313.64
in general payments reported to CMS, 2019-2025
21 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.90 · 2022: $441 · 2023: $1,398 · 2024: $1,900 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,844.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,817.66 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,149.47 | 2022-2025 | |
| Novo Nordisk INC | $551.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $532.89 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $511.08 | 2025 | Caplyta |
| Pfizer INC. | $278.28 | 2024-2025 | |
| Lilly USA, LLC | $276.83 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $221.55 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $172.37 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $172.26 | 2025 | Fanapt |
| Astellas Pharma US INC | $156.05 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $153.45 | 2022-2025 | Rexulti |
| Amgen INC. | $123.85 | 2021-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $32.39 | 2025 | Rexulti |
| Bioventus LLC | $30.37 | 2023 | Durolane |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $28.65 | 2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.56 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Dexcom, INC. | $23.04 | 2022 | |
| Organon LLC | $21.03 | 2024 | |
| Abbott Laboratories | $16.89 | 2025 | Id Now Instrument |
| Vertex Pharmaceuticals Incorporated | $16.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.